trending Market Intelligence /marketintelligence/en/news-insights/trending/x5j_putncfedz_z9wa4vvq2 content esgSubNav
In This List

Moberg Pharma names replacement for retiring chief medical officer

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Moberg Pharma names replacement for retiring chief medical officer

Moberg Pharma AB's Kjell Rensfeldt will retire as vice president of research and development and chief medical officer.

The Sweden-based pharmaceutical company said Rensfeldt will continue to serve as a senior adviser on a part-time basis following his retirement "during the fall," according to an Aug. 13 release.

Shaw Sorooshian will replace Rensfeldt as Moberg Pharma's vice president and chief medical officer. Sorooshian is joining the company from Swedish Orphan Biovitrum AB, a global rare disease company, where he served as senior director of global medical affairs. Prior to Sobi, he held senior roles at Shire PLC, H. Lundbeck A/S and Organon Laboratories Ltd.